Breast adenocarcinoma was the most represented primary disease site (32%), the majority of which were hormone receptor positive and HER2/neu negative (5 of 6 patients), followed by lung carcinoma (16%) and sarcoma (16%). Here, ERBB2 is linked to sarcoma.